Bosses at biotech firm Circassia have unveiled plans to float on the London Stock Exchange.

The firm, based at the Oxford Science Park, specialises in allergy treatments including those for cats and grass, using its ToleroMune technology.

Chief executive Steven Harris said: “This listing will be a major strategic step for Circassia.

“We believe our products can offer allergy patients an effective short course of immunotherapy with minimal side-effects and long-lasting benefits.

“We are immensely proud of our heritage and look forward to building a leading, UK-based specialty biopharmaceutical company.”

The firm is expected to float in March.